会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明授权
    • PURINE DERIVATIVES HAVING PHOSPHODIESTERASE IV INHIBITION ACTIVITY
    • WITH磷酸二酯酶IV阻燃性能的嘌呤衍生物
    • EP1045849B1
    • 2003-07-02
    • EP98963053.8
    • 1998-12-11
    • Euro-Celtique S.A.
    • CAVALLA, DavidCHASIN, MarkHOFER, PeterGEHRIG, AndreWINTERGERST, Peter
    • C07D473/34A61K31/52
    • C07D473/30C07D473/34
    • Disclosed are compounds of formula (I), wherein R3 is selected from the group consisting of C¿1-10? alkyl, C1-10 alkenyl, C3-10 cycloalkyl, C4-10 cycloalkylalkyl or C3-10 cycloalkenyl, wherein said alkyl, alkenyl, cycloalkyl, cycloalkylalkyl or cycloalkenyl is optionally substituted in one position with hydroxy; or benzyl, wherein said benzyl is optionally substituted in one or two positions with halogen, alkoxy, cycloalkoxy or polycycloalkyl, and wherein said alkyl moiety of said alkoxy or cycloalkoxy substituent is optionally substituted in one position with hydroxy; R?8¿ is selected from the group consisting of hydrogen, C¿1-10? alkyl, C1-10 alkenyl, C3-10 cycloalkyl, C4-10 cycloalkylalkyl or C3-10 cycloalkenyl, wherein said alkyl, alkenyl, cycloalkyl, cycloalkylalkyl or cycloalkenyl is optionally substituted in one position with hydroxy; or benzyl, wherein said benzyl is optionally substituted in one or two positions with halogen, alkoxy, cycloalkoxy or polycycloalkyl, and wherein said alkyl moiety of said alkoxy or cycloalkoxy is optionally substituted in one position with hydroxy; R?6a and R6b¿ are independently selected from the group consisting of hydrogen, C¿1-10? alkyl, C1-10 alkenyl, C3-10 cycloalkyl, C4-10 cycloalkylalkyl, or C3-10 cycloalkenyl, wherein said alkyl, alkenyl, cycloalkyl, cycloalkylalkyl or cycloalkenyl is optionally substituted in one position with hydroxy; and pharmaceutically acceptable salts thereof.
    • 8. 发明公开
    • PURINE DERIVATIVES HAVING PHOSPHODIESTERASE IV INHIBITION ACTIVITY
    • WITH磷酸二酯酶IV阻燃性能的嘌呤衍生物
    • EP1045849A1
    • 2000-10-25
    • EP98963053.8
    • 1998-12-11
    • Euro-Celtique S.A.
    • CAVALLA, DavidCHASIN, MarkHOFER, PeterGEHRIG, AndreWINTERGERST, Peter
    • C07D473/34A61K31/52
    • C07D473/30C07D473/34
    • Disclosed are compounds of formula (I), wherein R3 is selected from the group consisting of C¿1-10? alkyl, C1-10 alkenyl, C3-10 cycloalkyl, C4-10 cycloalkylalkyl or C3-10 cycloalkenyl, wherein said alkyl, alkenyl, cycloalkyl, cycloalkylalkyl or cycloalkenyl is optionally substituted in one position with hydroxy; or benzyl, wherein said benzyl is optionally substituted in one or two positions with halogen, alkoxy, cycloalkoxy or polycycloalkyl, and wherein said alkyl moiety of said alkoxy or cycloalkoxy substituent is optionally substituted in one position with hydroxy; R?8¿ is selected from the group consisting of hydrogen, C¿1-10? alkyl, C1-10 alkenyl, C3-10 cycloalkyl, C4-10 cycloalkylalkyl or C3-10 cycloalkenyl, wherein said alkyl, alkenyl, cycloalkyl, cycloalkylalkyl or cycloalkenyl is optionally substituted in one position with hydroxy; or benzyl, wherein said benzyl is optionally substituted in one or two positions with halogen, alkoxy, cycloalkoxy or polycycloalkyl, and wherein said alkyl moiety of said alkoxy or cycloalkoxy is optionally substituted in one position with hydroxy; R?6a and R6b¿ are independently selected from the group consisting of hydrogen, C¿1-10? alkyl, C1-10 alkenyl, C3-10 cycloalkyl, C4-10 cycloalkylalkyl, or C3-10 cycloalkenyl, wherein said alkyl, alkenyl, cycloalkyl, cycloalkylalkyl or cycloalkenyl is optionally substituted in one position with hydroxy; and pharmaceutically acceptable salts thereof.